41 results about "Organ Specificity" patented technology

The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins / transcripts in blood, biological tissue or other biological fluid.

Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.

The systems and methods disclosed herein are generally related to a cell culture system. More particularly, the systems and methods enable the culturing and interconnecting of a plurality of tissue types in a biomimetic environment. By culturing organ specific tissue types within a biomimetic environment and interconnecting each of the organ systems in a physiologically meaningful way, experiments can be conducted on in vitro cells that substantially mimic the responses of in vivo cell populations. In some implementations, the organ systems are fluidically connected with a constant-volume pump.

The invention provides improved methods for gene delivery to, or genetic modification of target cells, wherein the gene delivery or other genetic modification of the target cells is performed in the presence of endothelial cells, or after co-culture of the target cells with endothelial cells, or wherein co-culture of the target cells with endothelial cells is employed immediately alter gene delivery in order to "rescue" cells that may have been damaged during the gene delivery process. In some embodiments gene delivery is performed by transfection. In some embodiments gene delivery is performed by transduction, in some embodiments the endothelial cells are organ-specific endothelial cells. In some embodiments the endothelial cells are E4ORF1-expressing endothelial cells (E4ORF1+ECs). In some embodiments the target cells are stem cells, such as hematopoietic stem cells.

The present invention provides a method of extracting an organ- or tissue-specific highly expressed gene, including:(1) a step for measuring expression level of a specified gene group for each organ or tissue in 2 or more individuals,(2) a step for acquiring (a) a minimum value of expression levels in a particular organ or tissue in all individuals, and (b) a maximum value of expression levels in other organs and tissues in all individuals, for each gene, and(3) a step for extracting the gene as a gene highly expressed specifically in the particular organ or tissue if the above-described (a) / (b) ratio is larger than 1. By the present invention, truly organ- or tissue-specific genes are extracted.

The invention provides methods for analyzing and predicting the in vivo respiratory toxicity of a compound (e.g., pharmaceutical, biological, cosmetic, or chemical compounds) or composition comprising a combination of an in vitro mammalian cell model with multiple endpoint analysis, and time and concentration response curves. The methods allow the determination of a predicted in vivo respiratory toxicity value of a compound without the use of animals, with a high degree of accuracy. The methods comprise detecting any combination of cell viability markers and expression levels of genes implicated in respiratory toxicity and / or sensitization, such as pro-inflammatory response genes, combining the viability and gene expression level data with concentration response and time response data, conducting a computational analysis, and comparing test compound data to a database of known respiratory toxicants / sensitizers to predict and / or analyze the respiratory toxicity. An indication of organ specificity is provided by a toxicity index, which is determined by comparing mean 1050 values in lung cells to mean 1050 values in liver cells.

The invention relates to a newly discovered DNA sequence, which can be used as a promoter to regulate the specific expression of the target gene in the tissues and organs of the aboveground part of the plant in the form of light induction. The present invention clones the promoter sequence of the AtcpSecY2 gene from the model plant Arabidopsis thaliana, and then confirms in the transgenic Arabidopsis that the promoter can drive the GUS reporter gene to be specific in the tissues and organs of the aboveground parts of the plant in the form of light induction Express. The promoter of the present invention is used to construct a "promoter-target gene to be expressed" fusion gene, which can be transformed into a plant to obtain a transgenic plant with both plant aboveground tissues and organs and light-induced specific expression of the target gene. This not only helps to study the transcriptional regulation and expression mode of plant genes under light conditions, but also can be applied in plant genetic engineering to make exogenous genes moderately expressed under light conditions accompanied by plant physiological states, and at the same time accurately and effectively change the physiological state of plants. Photosynthetic characteristics and agronomic traits, to achieve strain improvement of crops, has a wide range of application value.